$MRK Citigroup sets PT at $65 https://stocknews.com/news/mrk-citigroup-sets-pt-at-65/
Merck &amp; Company given $65.00 PT by Citigroup Inc.. hold rating. http://www.marketbeat.com/r/845717 $MRK
Recent $MRK technical alerts: Non-ADX 1,2,3,4 Bullish... https://swingtradebot.com/equities/MRK
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Merck &amp; Company director just declared owning 5,100 shares of Merck &amp; Company  http://www.conferencecalltranscripts.org/4/summary2/?id=3940814 $MRK
Merck &amp; Company director just declared owning 6,351 shares of Merck &amp; Company  http://www.conferencecalltranscripts.org/4/summary2/?id=3940809 $MRK
Merck &amp; Company director just declared owning 100 shares of Merck &amp; Company  http://www.conferencecalltranscripts.org/4/summary/?id=3940808 $MRK
Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks https://benzinga.com/z/9739632 $GSK $MRK $PFE
Why Healthcare Was the Second-Biggest Gainer... http://marketrealist.com/?p=2183568 $JNJ $AMGN $XLV $MRK $PFE $SPX-INDEX $DJIA-INDEX
Non doomsday Nuclear attack by North Korea would lead to Biotechs/healthcare sectors soaring $bmy $jnj $mrk $pfe $xbi $ibb $cure $cncr $labu
Johnson &amp;amp; Johnson’s Consumer Business in 1Q17 http://marketrealist.com/?p=2178975 $AGN $GILD $JNJ $MRK $PJP
Merck &amp;amp; Co.’s Animal Health Segment&#39;s 1Q17 Revenues http://marketrealist.com/?p=2174874 $AMGN $JNJ $MRK $PFE $PWV
$MRK $PFE $BMY $EBIO same principal investigator for Bladder Cancer Trial. TLT or TLTFF. http://www.stockhouse.com/companies/bullboard?symbol=v.tlt&amp;postid=26434344
$GSK Inks $43 Million Deal to Use Artificial Intelligence To Develop Drugs https://t.co/bBxXh1ergL $JNJ $SNY $MRK
Johnson &amp;amp; Johnson’s Medical Devices Business in 1Q17 http://marketrealist.com/?p=2178960 $IXJ $JNJ $MDT $MRK $PFE
Merck’s Immunology and Cardiovascular Franchise in 1Q17 http://marketrealist.com/?p=2174866 $HDV $JNJ $LLY $MRK $PFE
$MRK ’s Keytruda, $LLY ’s Lartruvo Available via Cancer Drugs Fund for Sarcoma Patients in UK http://crweworld.com/article/pharma-biotech/113982/mercks-keytruda-lillys-lartruvo-available-via-cdf
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
Merck &amp; Company&#39;s sell rating reiterated at BMO Capital Markets. http://www.marketbeat.com/r/845191 $MRK
Merck &amp; Company Receives a Sell from BMO Capital $MRK http://www.analystratings.com/2017/07/04/merck-company-receives-a-sell-from-bmo-capital/490115/
$MRK target price 66.70$
Forecast from Dominant investors app
Performance of Merck’s Diabetes Drugs in 1Q17 http://marketrealist.com/?p=2174860 $AZN $BMY $IXJ $MRK $PFE
Johnson &amp;amp; Johnson’s Segment-Wise Performance in 1Q17 http://marketrealist.com/?p=2178889 $BMY $FHLC $JNJ $MRK $PFE
Imfinzi May Be AstraZeneca&#39;s Major Growth Driver http://marketrealist.com/?p=2178959 $AZN $BMY $MRK $RHHBY $VEA
Performance of Merck’s Gardasil and Other Human Vaccines in 1Q17 http://marketrealist.com/?p=2174844 $JNJ $LLY $MRK $PFE $XPH
$MRK Incyte &amp; Lilly&amp;apos;s Olumiant Gets Marketing Approval in Japan via https://finzine.com
Johnson &amp;amp; Johnson’s Revenues in 1Q17 http://marketrealist.com/?p=2178860 $AGN $IHE $JNJ $MRK $PFE
AstraZeneca Aims to Offer Multiple Therapies in NSCLC Segment http://marketrealist.com/?p=2176994 $AZN $BMY $MRK $RHHBY $VT
Keytruda&#39;s Developments in June 2017 http://marketrealist.com/?p=2174840 $INCY $MRK $NVO $PFE $PPH
Estimize EPS expectations are 5.36% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK target price 66.70$
Forecast from Dominant investors app
Estimize EPS expectations are 5.36% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK target price 66.70$
Forecast from Dominant investors app
Estimize EPS expectations are 5.36% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK target price 66.70$
Forecast from Dominant investors app
Estimize EPS expectations are 5.36% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK
https://www.stockwatch.com/News/Item.aspx?bid=U-b006004-U%3aMRK-20170705&amp;symbol=MRK&amp;region=U
BMO Capital reiterated Merck &amp; $MRK at Sell. This Dividend Discount Model implies stock&#39;s trading above fair value… https://t.co/Dy45v3q5FI
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK target price 66.70$
Forecast from Dominant investors app
$MRK Announces that the FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combinat… https://stocknews.com/news/mrk-announces-that-the-fda-has-placed-a-clinical-hold-on/
$MRK
https://www.stockwatch.com/News/Item.aspx?bid=U-b006004-U%3aMRK-20170705&amp;symbol=MRK&amp;region=U
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK target price 66.70$
Forecast from Dominant investors app
$MRK Merck Provides Further Update on Three Multiple Myeloma Studies Evaluating... via https://finzine.com
$MRK
https://www.stockwatch.com/News/Item.aspx?bid=U-b006004-U%3aMRK-20170705&amp;symbol=MRK&amp;region=U
$MRK:
New Insider Filing on
Director
ROCHELLE B LAZARUS:
http://insideri.com/1082206_000122520817012022_0001225208-17-012022
Estimize revenue expectations are 0.88% higher than that of Wall Street for $MRK Q2 [Reporting 07/28 BMO]
http://www.estimize.com/intro/mrk?utm_content=MRK&amp;amp;utm_medium=eps_update&amp;amp;utm_source=stocktwits#chart=historical
$MRK target price 66.70$
Forecast from Dominant investors app
